Company Profile
Ardelyx Stock Price, News & Catalysts
- Ticker:
- ARDX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.06 USD (0.00%)
Close
Last updated: August 17, 2026
1.36B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ARDX was little changed and closed at $4.06. No new same-company headline was identified in the current news window.
Company overview
NHE3 Inhibition Platform
Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption.
IBSRELA and XPHOZAH
IBSRELA is approved for irritable bowel syndrome with constipation, while XPHOZAH is approved to lower serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response or intolerance to phosphate binders. Both products contain tenapanor.
Pipeline Expansion
The Phase 3 ACCEL trial is evaluating IBSRELA in adults with chronic idiopathic constipation. RDX10531 is a next-generation NHE3 inhibitor being explored across additional therapeutic applications.
Future catalysts
- Completion of enrollment in the Phase 3 ACCEL trial expected by year-end 2026.
- Topline ACCEL results expected in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ardelyx (ARDX)?
Ardelyx (ARDX) most recently closed at 4.06 USD, a 0.00% move versus the previous session.
What is the market cap of Ardelyx (ARDX)?
Ardelyx currently has a market capitalization of 1.36B USD on BioPharmSignal.
What does Ardelyx do?
NHE3 Inhibition Platform Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption. IBSRELA and XPHOZAH IBSRELA is approved for irritable bowel syndrome with constipation, while...
On which exchange is ARDX stock listed?
Ardelyx (ARDX) is associated with NASDAQ, United States, Biopharma.
What is NHE3?
NHE3 Inhibition Platform Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract.
Which conditions is Ardelyx targeting with NHE3?
NHE3 Inhibition Platform Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption. IBSRELA and XPHOZAH IBSRELA is approved for irritable bowel syndrome with constipation, while...
How does Ardelyx describe recent progress with NHE3?
Completion of enrollment in the Phase 3 ACCEL trial expected by year-end 2026. Topline ACCEL results expected in the second half of 2027.
What is Inhibition?
NHE3 Inhibition Platform Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract.